Altimmune, Inc.

ALTSEC EDGAR

Pharmaceutical Preparations(DE)CIK: 1326190

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue from Contract with Customer, Excluding Assessed Tax	—	—	—	—	$8.2M
Research and Development Expense	$82.2M	$65.8M	$70.5M	$74.5M	$49.8M
Operating Expenses	$103.2M	$96.4M	$87.7M	$101.3M	$63.0M
Operating Income (Loss)	-$103.2M	-$95.9M	-$87.7M	-$96.9M	-$54.8M
Interest Expense	—	—	$8.0K	$5.0K	$9.4K
Nonoperating Income (Expense)	$8.1M	$7.5M	$2.8M	-$176.0K	$337.2K
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	-$95.1M	-$88.4M	-$84.9M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$139.3M	$210.6M	$206.9M	$218.9M	$245.1M
Assets, Current	$137.3M	$209.6M	$192.8M	$204.1M	$230.3M
Cash and Cash Equivalents, at Carrying Value	$36.9M	$135.1M	$111.1M	$190.3M	$115.9M
Accounts Receivable, after Allowance for Credit Loss, Current	—	—	—	—	—
Liabilities	$15.8M	$16.5M	$21.6M	$19.7M	$19.2M
Liabilities, Current	$10.5M	$12.1M	$17.1M	$18.3M	$12.0M
Long-term Debt	—	—	—	—	—

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	-$79.8M	-$75.8M	-$62.6M	-$78.2M	-$34.3M
Net Cash Provided by (Used in) Investing Activities	-$28.4M	$13.7M	-$73.4M	$87.5M	-$72.2M
Net Cash Provided by (Used in) Financing Activities	$10.0M	$86.1M	$56.8M	$65.1M	$213.5M
Payments to Acquire Property, Plant, and Equipment	$11.0K	$47.0K	$126.0K	$12.1M	$204.0K

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)